In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp.

Medical Mycology

Volumn 47, Issue 5, 2009, Pages 457-462

  Shalit, Itamar ^a,b   Shadkchan, Yona ^a   Mircus, Gabriel ^a   Osherov, Nir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Caspofungin; Fusarium; Synergy; Tacrolimus; Terbinafine

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; TACROLIMUS; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; FUNGAL VIABILITY; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUNGUS HYPHAE; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; GROWTH RATE; MICROSCOPY; MINIMAL EFFECTIVE CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAINING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG SYNERGISM; ECHINOCANDINS; FUSARIUM; HUMANS; HYPHAE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PYRIMIDINES; TACROLIMUS; TRIAZOLES;

ANIMALIA; FUNGI; FUSARIUM;

EID: 70749108676     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802232910     Document Type: Article

References (12)

1. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol 2007; 20: 695-704.
2. Ho DY, Lee JD, Rosso F, et al. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50: 227-231.
3. Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin. Clin Infect Dis 2003; 36: 1349-1350.
4. Vagace JM, Sanz-Rodriguez C, Casado MS, et al. Resolution of disseminated fusariosis in a child with acute leukemia treated withcombined antifungal therapy: a case report. BMC Infect Dis 2007; 7: 40.
5. Spellberg B, Schwartz J, Fu Y, et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 2006; 58: 973-979.
6. Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother 2002; 46: 245-247.
7. Ortoneda M, Capilla J, Javier Pastor F, et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004; 48: 69-71. (Pubitemid 38167503)
8. Kontoyiannis DP, Lewis RE, Osherov N, et al. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003; 51: 313-316.
9. Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI Broth Microdilution Susceptibility Method (M38-A Document) for Amphotericin B, Itraconazole, Posaconazole, and Voriconazole. J Clin Microbiol 2005; 43: 5243-5246.
10. Shalit I, Shadkchan Y, Samra Z, et al. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother 2003; 47: 1416-1418.
11. Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004; 83: 394-397.
12. Steinbach WJ, Reedy JL, Cramer RA Jr, et al. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 2007; 5: 418-430.